Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre, Retrospective Study Assessing Durvalumab as Consolidation Treatment for Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) Following by Sequential Chemoradiotherapy (sCRT)

NCT07309211 is registered in ClinicalTrials.gov with The First Affiliated Hospital with Nanjing Medical University as lead sponsor.

NCT NCT07309211
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07309211 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre, Retrospective Study Assessing Durvalumab as Consolidation Treatment for Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) Following by Sequential Chemoradiotherapy (sCRT)
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University
Phase
Observational
Overall status
Recruiting
Start date
July 8, 2025
Completion date
December 31, 2026
Enrollment
25 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

sclc, limited stage